RW experience with CGRP antogonists at a tertiary headache center

Key messages

• Real-world data are needed to supplement the efficacy and safety demonstrated in Phase 3 randomized controlled trials of the calcitonin gene-related peptide (CRGP) antagonists ubrogepant, rimegepant, and lasmiditan.
• Preliminary real-world data collected at a tertiary headache center show ubrogepant provides headache freedom and pain relief at 2 hours for at least one attack in a predominantly chronic migraine patient population.
• The final results from the present study will provide important clinical evidence that will inform decision­making in clinical practice.